Department of Anesthesiology and Pain Medicine, Hanyang University Hospital, 222, Wangsimni-ro, Seongdong-gu, Seoul, 133-792, Republic of Korea.
Can J Anaesth. 2017 Sep;64(9):947-961. doi: 10.1007/s12630-017-0917-x. Epub 2017 Jun 21.
Intranasal dexmedetomidine premedication is a newly introduced method for reducing stress and anxiety before general anesthesia in children. We performed a meta-analysis to identify the effects of intranasal dexmedetomidine premedication in children.
We conducted a systematic review to find published randomized-controlled trials using intranasal dexmedetomidine as premedication. We searched databases in EMBASE™, MEDLINE®, and the Cochrane Controlled Trials Register using the Ovid platform. This study was conducted based on the Cochrane Review Methods.
This review included 1,168 participants in 13 studies. Intranasal dexmedetomidine premedication provided more satisfactory sedation at parent separation (relative risk [RR], 1.45; 95% confidence interval [CI], 1.19 to 1.76; P = 0.0002; I = 80%) than other premedication regimes. In addition, it reduced the need for rescue analgesics (RR, 0.58; 95% CI, 0.40 to 0.83; P = 0.003; I = 0%). Nevertheless, there were no differences in sedation at mask induction (RR, 1.25; 95% CI, 0.98 to 1.59; P = 0.08; I =71%) or in the incidence of emergence delirium (RR, 0.52; 95% CI, 0.24 to 1.13; P = 0.10; I = 67%). Intranasal dexmedetomidine was associated with a significantly lower incidence of nasal irritation (RR, 0.05; 95% CI, 0.01 to 0.36; P = 0.003; I = 0%) and postoperative nausea and vomiting (RR, 0.63; 95% CI, 0.40 to 0.99; P = 0.04; I = 0%) than other premedication treatments. It also showed significantly lower systolic blood pressure (weighted mean difference [WMD], -6.7 mmHg; 95% CI, -10.5 to -2.9; P = 0.0006; I = 96%) and heart rate (WMD, -6.8 beats·min; 95% CI, -11.3 to -2.6; P = 0.002; I = 98%).
Intranasal dexmedetomidine provided more satisfactory sedation at parent separation and reduced the need for rescue analgesics and the incidence of nasal irritation and postoperative nausea and vomiting when compared with other premedication treatments.
鼻内给予右美托咪定作为术前用药是一种新引入的方法,可减少儿童全身麻醉前的应激和焦虑。我们进行了一项荟萃分析,以确定鼻内给予右美托咪定作为术前用药的效果。
我们进行了一项系统评价,以寻找使用鼻内给予右美托咪定作为术前用药的已发表的随机对照试验。我们使用 Ovid 平台在 EMBASE™、MEDLINE® 和 Cochrane 对照试验登记处进行了数据库搜索。这项研究是根据 Cochrane 综述方法进行的。
本综述包括 13 项研究中的 1168 名参与者。与其他术前用药相比,鼻内给予右美托咪定作为术前用药在与父母分离时提供了更满意的镇静效果(相对风险 [RR],1.45;95%置信区间 [CI],1.19 至 1.76;P = 0.0002;I = 80%)。此外,它减少了对抢救性镇痛药的需求(RR,0.58;95%CI,0.40 至 0.83;P = 0.003;I = 0%)。然而,在面罩诱导时镇静(RR,1.25;95%CI,0.98 至 1.59;P = 0.08;I = 71%)或苏醒性谵妄发生率(RR,0.52;95%CI,0.24 至 1.13;P = 0.10;I = 67%)方面,两组之间没有差异。鼻内给予右美托咪定与显著较低的鼻刺激发生率(RR,0.05;95%CI,0.01 至 0.36;P = 0.003;I = 0%)和术后恶心呕吐(RR,0.63;95%CI,0.40 至 0.99;P = 0.04;I = 0%)有关,与其他术前用药相比。它还显示出显著更低的收缩压(加权均数差 [WMD],-6.7mmHg;95%CI,-10.5 至 -2.9;P = 0.0006;I = 96%)和心率(WMD,-6.8 次/分钟;95%CI,-11.3 至 -2.6;P = 0.002;I = 98%)。
与其他术前用药相比,鼻内给予右美托咪定可提供更满意的与父母分离时的镇静效果,减少对抢救性镇痛药的需求,降低鼻刺激和术后恶心呕吐的发生率。